Abbvie Inc., of North Chicago, and Calico, the Google-backed life sciences firm led by Arthur D. Levinson and Hal V. Barron, inked an R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegenerative diseases and cancer. Under the agreement, the companies will combine their complementary strengths to accelerate the availability of new therapies for age-related diseases. Each will provide up to an initial $250 million, with the potential for both sides to contribute an additional $500 million. Calico will be responsible for R&D and early development during the first five years and continue to advance projects through phase IIa for a 10-year period, while Abbvie will support those R&D efforts and, following completion of phase IIa, will have the option to manage late-stage development and commercialization activities. Both parties will share costs and profits equally.
Eisai Inc., of Woodcliff Lake, N.J., said it entered an agreement with Concordia Pharmaceuticals Inc., of Barbados, a subsidiary of Concordia Healthcare Corp., to purchase Eisai's U.S. and Puerto Rican commercialization and distribution rights to epilepsy drug Zonegran (zonisamide). Under the terms, Eisai will receive full payment from Concordia upon closing and the two firms are expected to enter a supply agreement under which Eisai will serve as Concordia's supplier of Zonegran for the U.S. and Puerto Rican markets.
Teva Pharmaceutical Industries Ltd., of Jerusalem, reported positive judgment from the UK High Court in support of its case against London-based Astrazeneca plc relating to the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for Astrazeneca's fixed-dose formoterol/budesonide combination product, Symbicort. The court agreed that Astrazeneca's patent covering the SMART indication of Symbicort was obvious, and rejected Astrazeneca's proposed amendments to the patent on the basis that they added matter. Teva said the case was brought to facilitate its European launch of its formoterol/budesonide fixed-combination product, DuoResp Spiromax, which utilizes Teva's iSpiromax device technology.